Subject, city, state	Effective date
N OLMSTED, OH	
DEFAULT ON HEAL LOAN	
ALEXANDER, MICHAEL A ..... ALIQUIPPA, PA	02/20/2002
ARGUEDAS, WALTER G ..... HIALEAH, FL	02/20/2002
BELLER, BRYAN D ..... SOUTHGATE, MI	02/20/2002
CAFAGNA, MARK WILLIAM SR ..... WEST HILLS, CA	02/20/2002
CAGLE, LARRY S ..... AHOSKIE, NC	02/20/2002
CARR, GUY A ..... HUTCHINSON, KS	02/20/2002
CONSTANTINESCU, SERBAN CRISTIA ..... PHILADELPHIA, PA	02/20/2002
COOPER, SHIRLEY T ..... LANSDALE, PA	02/20/2002
CRAIG, BRADLEY D ..... SNOWFLAKE, AZ	02/20/2002
DE JESUS–MIRANDA, LUIS A SAN JUAN, PR	02/20/2002
DIENER, ROBERT B ..... AUBURNDALE, MA	02/20/2002
DONELSON, RICHARD BARTON ..... PHOENIX, AZ	02/20/2002
EATON, GARY D ..... SPRINGFIELD, MO	02/20/2002
ELLZEY, PAUL D ..... PRATTVILLE, AL	02/20/2002
FISHBOUGH, ROSS E ..... BENSLAEM, PA	02/20/2002
FLOYD, THOMAS PARKER .... TRUFANT, MI	02/20/2002
GREETHONG, KITIMAN ..... IRVINE, CA	02/20/2002
HAGEN, CALVIN P ..... KANSAS CITY, MO	02/20/2002
HANSEN, KRIS T ..... ST GEORGE, UT	02/20/2002
HORNIG–ROHAN, JAMES EDWARD ..... SENECA, SC	02/20/2002
IBRIK, AMIR ..... SYRACUSE, NY	02/20/2002
KALMAN, BETSY S ..... RICHMOND HILL, NY	02/20/2002
KRUGMAN, LINDA L ..... LEXINGTON, KY	02/20/2002
LE SAGE, SAHARA ADAMS ... LEAGUE CITY, TX	02/20/2002
LEONELLI, DAVID ROMAN SR LOS ANGELES, CA	02/20/2002
LEWIS, STEVEN R ..... IRVING, TX	02/20/2002
LINSTEADT, ELIZABETH M .... DENISON, TX	02/20/2002
LUCEY, TIMOTHY D ..... NEWBURGH, NY	02/20/2002
MARTINEZ, DANIEL A ..... REDLANDS, CA	02/20/2002
MASSAKOWSKI, EDWARD A BENSALEM, PA	02/20/2002
MCGHEE, STEPHANIE Y ..... HOUSTON, TX	02/20/2002
MCINNES, THOMAS K ..... POOLESVILLE, MD	02/20/2002
MEINHOLD, STEVEN DALE .... OMAHA, NE	02/20/2002
MONICA, JULIANNE H ..... SPRING LAKE, NJ	02/20/2002
NEWELL, DAVID CLIFFORD ... FORT BRAGG, CA	02/20/2002
OWCZAREK, KEITH VINCENT MARYSVILLE, WA	02/20/2002
PATT, RICHARD H ..... NEW YORK, NY	02/20/2002
PEISS, STUART ..... HOFFMAN ESTATES, IL	02/20/2002
PHILLIPS, THADDEUS HILLARD III ..... SAN ANTONIO, TX	02/20/2002
PORTNOW, ROBERT THOMAS ..... CLEVELAND, OH	02/20/2002
RAMU, NALAYA ..... LOS ANGELES, CA	02/20/2002
RASHTI, KOUROS ..... TARZANA, CA	02/20/2002
RICHBERG, MARK H ..... PHILADELPHIA, PA	02/20/2002
RIGNEY, MARK EDWARD ..... OKLAHOMA CITY, OK	02/20/2002
ROMERO, JOHN JOSEPH ..... ALBURQUERQUE, NM	02/20/2002
RORRER, MARK TIMOTHY .... CLAYTON, OH	02/20/2002
ROZENBERG, RONALD L ..... LEVITTOWN, NY	02/20/2002
RUSSELL, BILL ..... ST LOUIS, MO	02/20/2002
SAID, SAED M ..... DUNIONVILLE, CT	12/18/2001
SANDOR, GEORGE JOSEPH NEW YORK, NY	02/20/2002
SAUTMAN, SATPAL K ..... PLANTATION, FL	02/20/2002
SCHWARTZ, FRANCIS XAVIER JR ..... OAKLAND, CA	02/20/2002
SCHWARZ–MANDRACCHIA, DENISE MA ..... WINTERSET, IA	02/20/2002
SLOTNICK, ROBIN T ..... CLEVELAND, OH	02/20/2002
STOCK, ANN M ..... BELLEVILLE, IL	02/20/2002
THOMPSON, JANETTE A ..... SILVER SPRING, MD	02/20/2002
TOLIVER, EDWARD C ..... CHICAGO, IL	02/20/2002
VESTICH, GEORGE T ..... RICHMOND, OH	02/20/2002
VILLANO, GUY JOHN ..... NISKAYUNA, NY	02/20/2002
WALCHER, KEVIN RAY ..... BOOKER, TX	02/20/2002
WALTERS, BRIAN D JR ..... SEATTLE, WA	02/20/2002
WAN, JAMES Y ..... MOBILE, AL	02/20/2002
WHEDBEE, JOSEPH IRELAND ..... REDLANDS, CA	02/20/2002
WILLIAMS, ERIC A ..... TOWSON, MD	02/20/2002
WILSON, RONALD E ..... DETROIT, MI	02/20/2002
YODER, KYLE JAY ..... REDWOOD CITY, CA	02/20/2002
ZIMMERMAN, MARY L P ..... OCONOMOWOL, WI	02/20/2002

Dated: March 4, 2002.

Calvin Anderson, Jr.,

Director, Health Care Administrative Sanctions, Office of Inspector General.

[FR Doc. 02–5944 Filed 3–12–02; 8:45 am]

BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Policies of Academic Institutions Regarding Tobacco Industry Research Funding

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the national Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection

Title: Policies of Academic Institutions Regarding Tobacco Industry Research Funding.

Type of Information Collection Request: NEW.

Need and Use of Information Collection: This study will assess current administrative policies of medical schools and schools of public health regarding faculty acceptance of research funding from tobacco manufacturers and trade organizations. The primary objectives of the study are to assess how many institutions have a tobacco-specific research funding policy, their reasons for adopting or not adopting such a policy, and what the requirements of those policies are. The finding will provide valuable information concerning: (1) How academic institutions have responded to concerns about researchers' funding relationships in tobacco research, (2) administrators' attitudes towards research funding policies targeted at tobacco specifically; and (3) what types of requirements have been imposed on academic researchers regarding tobacco funding.

Frequency of Response: Once.

Affected Public: Individuals; academic institutions.

Type of Respondents: academic administrators.

The annual reporting burden is as follows:

Estimated Number of Respondents: 156.

Estimated Number of Responses per Respondent: 1.

Average Burden Hours Per Response: .5.

Estimated Total Annual Burden Hours Requested: 78.

The annualized cost to respondents is estimated at: $780. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Mark Parascandola, Cancer Prevention Fellow, OPO, DCP, NCI, NIH, 6130 Executive Boulevard, Suite 3109, Bethesda, MD 20892, or call non-toll-free number (301) 594–1576 or E-mail your request, including your address to: *paramark@mail.nih.gov.*

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before May 13, 2002.

Dated: February 19, 2002.

Reesa L. Nichols,

NCI Project Clearance Liaison.

[FR Doc. 02–5930 Filed 3–12–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Artificial Chromosomes That Can Shuttle Between Bacteria, Yeast, and Mammalian Cells

Larionov et al. (NCI)

DHHS Reference No. E–253–00/0 filed April 6, 2001

Licensing Contact: Pradeep Ghosh; 301/496–7736 ext. 211; e-mail *ghoshp@od.nih.gov*.

Development of a novel cloning system in mammalian cells based on Mammalian Artificial Chromosome (MAC) may have profound effects on human gene therapy. The technology described in invention pertains to methods and compositions that allow for the selective isolation of centromeric regions from mammalian chromosomes, including those of humans. Also included in the invention are cloned and characterized centromeric regions of humans and other mammalian chromosomes. The isolation of these centromeric regions provides a material for engineering of MACs that are capable of being shuttled between bacterial, yeast and mammalian cells, such as human cells. These MACs may serve as effective tools for the characterization of cis-active loci controlling transmission of mammalian chromosomes. The present invention has broad utilities in studies related to genetic diseases. It can be used for studying of expression of entire copies of human genes. Gene therapy may have therapeutic and preventative applications and a range of gene therapy approaches are currently being evaluated for treatment of cancer and a large number of autoimmune and genetic disorders. Gene therapy necessitates an efficient system for gene delivery. The MACs constructed in this invention provide useful vehicles for the delivery and expression of transgenes within cells. Thus, the present invention provides a novel method allowing a direct isolation of mammalian centromeres and efficient system for gene delivery associated with gene therapy.

Treatment of Pain Based on Parathyroid Hormone-2 (PTH2) Receptors

Ted B. Usdin (NIMH)

DHHS Reference No. E–079–01/0 filed Jun 13 2001

Licensing Contact: Norbert Pontzer; 301/496–7736 ext. 284; e-mail: *np59n@nih.gov*.

Current medications for pain, especially chronic pain, are only partially effective and can involve unacceptable side effects. A unique receptor (PTH2) and an endogenous ligand (TIP39) which binds to the receptor were previously discovered by this inventor. The PTH2 receptor and the endogenous ligand were found to have an anatomical distribution suggesting a role in nociception. The PTH2 receptor is present at relatively high levels in nerve terminals within the outer layers of the dorsal horn of the spinal cord where it is primarily coupled to generation of cAMP (Usdin, T.B., et al., 1999, *Nature Neurosci.* 2: 941–943; Wang, T., et al, 2000, *Neuroscience* 100: 629–49; Usdin, T.B., et al, 2000, *Front Neuroendocrinol* 21: 349–83) The DRG neurons that project to this area are largely nociceptors and this region contains the central nervous system neurons they activate. Most receptors present in the central terminals of DRG neurons are also found in their peripheral terminals. Thus, activation of the PTH2 receptor could modulate peripheral excitation of nociceptors, neurotransmitter release from their central terminals in the spinal cord, and some of their postsynaptic effects.

This inventor has now shown the PTH2 receptor system to have very potent actions in animal tests of nociception. Both peripheral and